Media
Corgentech Appoints Daniel Gennevois, M.D., Vice President of Medical Affairs
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2003 -- Corgentech Inc., a privately-held biotechnology company, announced today that Daniel Gennevois, M.D., has been appointed vice president of medical affairs. Dr. Gennevois has held a number of top clinical positions with leading biotechnology and pharmaceutical companies, including Roche Bioscience, Chiron Vaccines and Syntex Corporation.
At Corgentech, Dr. Gennevois will oversee the company's pivotal Phase 3 clinical trial studying its lead product, CGT003, an E2F Decoy therapy to prevent graft failure following coronary artery bypass graft (CABG) surgery. This trial is being conducted at approximately 100 leading medical centers in the United States and will soon complete enrollment of 3,000 patients. In addition to the CABG trial, Dr. Gennevois will have a broad clinical role, designing and conducting other trials, planning clinical development programs in other indications, preparing scientific and regulatory submissions and preparing for the commercial launch of CGT003.
"Daniel brings more than 20 years of basic and clinical research experience in industry, government and academia. His strong background in drug development and wealth of experience planning, designing and coordinating worldwide clinical programs will be critical to Corgentech as we work to complete our pivotal Phase 3 program," said John P. McLaughlin, Corgentech's president and chief executive officer. "He also brings expertise in preparing submissions and serving as an effective representative to health authorities in North America and Europe, experience that will prove valuable as we formulate filing strategies for our lead product."
Prior to joining Corgentech, Dr. Gennevois served as vice president of clinical operations at Dynavax Technologies where he globally managed all clinical development programs of the company in allergy, asthma, oncology and vaccines. As senior director of clinical research for Roche Bioscience, he worked closely with pre-clinical research groups to identify lead clinical candidates, planned and designed clinical trial protocols, filed investigational new drug applications and monitored study conduct for indications in pain treatment and urology.
Previously, he served as director of clinical research for Chiron Vaccines, where he designed clinical plans and conducted early- to late-stage clinical trials. He also functioned as clinical program leader on these multicenter, multinational trials and contributed to the preparation of filing packages to United States and European regulatory agencies. Dr. Gennevois also served as director of medical research for Syntex Corporation, where he provided medical expertise on a number of cardiovascular programs. He also served as associate director of clinical and business development for American Bioproducts Co., and scientific manager for Porton Products.
In the academic setting, he conducted basic research in infectious disease and immunology at the University of California at Berkeley's school of public health and in antiviral agents at the National Laboratory of the French Ministry of Health. Dr. Gennevois holds a doctor of medicine degree from the University of Lyon, Claude Bernard School of Medicine in Lyon, France and completed clinical training in infectious disease at the Hospital Edouard Herriot, also in Lyon.
About Corgentech Inc.
Corgentech Inc. is a privately-held biotechnology company that is the leader in the discovery, development and commercialization of an exciting and powerful new class of therapeutics called transcription factor decoys or TF Decoys. The company's proprietary technology platform is capable of delivering multiple new product candidates to treat diseases that affect large patient populations in a relatively short period of time. Corgentech is based in South San Francisco, Calif. For more information, visit www.corgentech.com.
| Contacts: | |
| Richard Powers Corgentech |
Kristin Nash WeissCom Partners |
| 650-624-9600 [email protected] |
415-302-7951 [email protected] |
